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Abstract
Background: The CCR2/CCL2 system has been identified as a regulator in the pathogenesis of neuropathy-
induced pain. However, CCR2 target validation in analgesia and the mechanism underlying antinociception
produced by CCR2 antagonists remains poorly understood. In this study, in vitro and in vivo pharmacological
approaches using a novel CCR2 antagonist, AZ889, strengthened the hypothesis of a CCR2 contribution to
neuropathic pain and provided confidence over the possibilities to treat neuropathic pain with CCR2 antagonists.
Results: We provided evidence that dorsal root ganglia (DRG) cells harvested from CCI animals responded to
stimulation by CCL2 with a concentration-dependent calcium rise involving PLC-dependent internal stores. This
response was associated with an increase in evoked neuronal action potentials suggesting these cells were
sensitive to CCR2 signalling. Importantly, treatment with AZ889 abolished CCL2-evoked excitation confirming that
this activity is CCR2-mediated. Neuronal and non-neuronal cells in the spinal cord were also excited by CCL2
applications indicating an important role of spinal CCR2 in neuropathic pain. We next showed that in vivo spinal
intrathecal injection of AZ889 produced dose-dependent analgesia in CCI rats. Additionally, application of AZ889 to
the exposed spinal cord inhibited evoked neuronal activity and confirmed that CCR2-mediated analgesia involved
predominantly the spinal cord. Furthermore, AZ889 abolished NMDA-dependent wind-up of spinal withdrawal
reflex pathway in neuropathic animals giving insight into the spinal mechanism underlying the analgesic properties
of AZ889.
Conclusions: Overall, this study strengthens the important role of CCR2 in neuropathic pain and highlights
feasibility that interfering on this mechanism at the spinal level with a selective antagonist can provide new
analgesia opportunities.
Background
Neuropathic pain treatment is often refractory to avail-
able therapies and its underlying mechanisms remain
poorly understood. This pathological state reflects
abnormal sensory processes caused by a variety of cellu-
lar changes that result in abnormal hyperexcitability,
hyperactivity and spontaneous activity in the pain circui-
try [1]. Many molecular events have been implicated for
their contribution to neuropathic pain. The CC chemo-
kine ligand 2 (CCL2 or monocyte chemoattractant pro-
tein-1/MCP-1) and its CC chemokine receptor (CCR2)
are of interest as they have recently been shown to be
overexpressed in glial and neuronal cells following injury
to the nervous system and may contribute to the neu-
roinflammatory processes associated with the develop-
ment and maintenance of neuropathic pain [2-14]. In
addition, mice lacking CCR2 receptors failed to show
mechanical allodynia in the partial nerve injury model
[2] while antagonists of CCR2 reversed nociceptive
responses in the spinal nerve ligation and varicella zos-
ter animal model [15] as well as in the focal demyelina-
tion of the sciatic nerve model of neuropathic pain [4].
Although a growing body of evidence suggests that
interventions aiming to block CCR2/CCL2 signalling
may alleviate neuropathic pain, little is known about the
actual cellular site of action of this effect. So far, there
appears to be a disagreement on the site of action of
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provided evidence that peripheral and central nervous
system (CNS) mechanisms may be involved. Some stu-
dies have suggested that both resident and infiltrating
spinal microglia activated by CCR2 [14] contributed to
enhanced neuronal excitation [16] during the develop-
ment of nerve injury induced neuropathy. Others sug-
gested that CCR2 antagonists can inhibit activation of
the sciatic nerve and DRG neurons which supports a
peripherally-mediated analgesia mechanism [17]. Finally,
DRG neurons activated by CCL2 could perhaps contri-
bute to both centrally- and peripherally-mediated patho-
physiology [18-20].
Here we provide further details on the cellular and
pharmacological mechanisms of CCL2/CCR2 signalling
in a model of neuropathic pain through the integration
of cellular imaging, electrophysiology as well as the use
of AZ889, a competitive CCR2 blocker. In addition, the
behavioural evaluation of AZ889 in the CCI model of
neuropathic pain was supplemented via critical pharma-
cokinetic measures of drug exposure that strengthened
the in vitro to in vivo translation of pharmacological
properties.
Results
Identification of the potent CCR2 antagonist
Chemokine receptors are known to modulate intracellu-
lar calcium concentration [21]. A library of designed
molecules was screened on HEK cells expressing the
receptor using a calcium flux-assay (FLIPR). Compounds
capable of blocking the intracellular calcium rise evoked
by mouse CCL2 in HEK293 s cells (Gaqi5) stably
expressing the rat CCR2 receptor were selected and
further profiled by performing dose-response curves.
Mouse and rat CCL2 (mCCL2 and rCCL2) purchased
from R&D Systems gave similar median effective con-
centrations (EC50) values (Additional file 1 Figure S1)
and mCCL2 was selected to conduct the screening
assay. Cells were pre-incubated (30 min) with a given
concentration of compound (from 0.04 to 1 μM) and
CCR2 calcium-mediated activation was evoked by the
addition of mCCL2 (EC50 concentration, 1 nM).
A potent antagonist, AZ889, was identified for competi-
tively inhibiting mCCL2-evoked calcium response with
an observed median inhibition concentration (IC50)
potency value of 1.3 ± 0.2 nM (n = 5; Figure 1).
The selectivity of AZ889 was further assessed using a
broad panel of targets, including (G protein-coupled
receptors) GPCRs, ligand-gated receptors, ion channels,
transporters and enzymes. AZ889 was inactive (less than
50% effect at 10 μM) on all targets (Additional file 2
Table S1). Since the rat CCR2 receptor shares 85%
homology at the amino acid level with CCR5, AZ889
was further profiled on CHO cells stably expressing rat
CCR5 and stimulated with the CCR5 ligand macrophage
inflammatory protein 1alpha (MIP-1a). Using the cal-
cium-mobilization assay, AZ889 caused a concentration-
dependent inhibition of MIP-1a-evoked responses with
an IC50 value of 79 nM confirming AZ889 has 60-fold
selectivity for CCR2 as compared to CCR5 (data not
shown).
Modulation of DRG neuron firing by CCL2
Previous studies have reported that rat DRG neurons
from chronic compression of DRG (CCD) neuropathic
model are activated by CCL2 applications which triggers
an increase in action potentials generated in these
Figure 1 mCCL2-induced intracellular calcium mobilization in
HEK293 s cells expressing CCR2 is blocked by compound
AZ889. (A) Mouse derivative of CCL2 evoked calcium activation of
HEK293 s cells expressing CCR2 with an EC50 value of 1 nM.
Calcium mobilization was recorded on a FLIPR system. (B) AZ889
dose-dependently inhibited CCR2-mediated calcium response
evoked by 1 nM of mCCL2 with an IC50 value of 1.3 ± 0.2 nM (n =
5). The values were normalized to control mCCL2-evoked responses.
The data shown is the average of 3 independent experiments.
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with chronic constriction injury (CCI) were also CCL2-
sensitive, we performed whole-cell patch clamp record-
ings to evaluate the effect of the chemokine on cell
excitability. A suprathreshold (500 ms) depolarizing
current step was used to evoke a stable baseline of
action potentials (Figure 2A) in the absence or presence
of locally applied CCL2 (1min) onto the recorded cell.
CCL2 at 10 nM produced a reversible 29 ± 9% increase
in evoked firing compared to vehicle (p <0 . 0 1 ,n=3 ,
Figure 2A). The maximal concentration of 100 nM
rCCL2 facilitated neuronal firing by 46 ± 13% (p <0 . 0 1 ,
n = 6). Application of the selective CCR2 receptor
antagonist, AZ889 (100 nM), did not affect evoked neu-
ronal firing (Figure 2B, n = 6). However, pre-treatment
with AZ889 (100 nM) prior to local application of
rCCL2 (100 nM) completely prevented the agonist-
induced increase in firing (p <0 . 0 1 ,n=1 3 ;F i g u r e2 B )
confirming that rCCL2 effects were mediated by CCR2.
The rCCL2-activated DRG neurons were all sensitive to
transient receptor potential channel V1 (TRPV1) agonist
capsaicin suggesting these cells were small nociceptive
neurons (data not shown).
CCL2 evokes calcium-mediated activation of both
neuronal and non-neuronal cells from CCI rats
An increased number of action potentials in DRG neu-
rons following CCR2 activation is an intriguing obser-
vation since CCR2 is a pertussis toxin (PTX)-sensitive
GPCR coupled to inhibitory Gi and/or Gq [22,23].
Additionally, CCR2 activation evokes excitatory Ca
2+
rises in DRG cells [4,24] but the underlying mechan-
ism is still poorly understood. To gain further insight
into CCR2-mediated Ca
2+ mobilization, we next evalu-
ated the sensitivity of both neuronal and non-neuronal
cell types in the DRG by recording changes in intracel-
lular calcium evoked by CCL2. Interestingly, CCL2 did
not evoke any response in DRG cells harvested from
naive rats (data not shown). In mixed-cell cultures
from CCI rats, CCL2 evoked an intracellular calcium
rise in both neuronal and non-neuronal DRG cells
(Figure 3A-C). Non-neuronal cells, satellite cells or
microglia, were easily distinguished from neurons by
their size, morphology and absence of dendritic pro-
cesses (Figure 3A). The amplitude of the calcium rise
evoked by rCCL2 in cultured DRG cells was concen-
tration-dependent and the calculated EC50 value was
59.6 nM in neurons and 56.7 nM in non-neuronal
cells confirming both DRG cell types were CCL2-sensi-
tive (Figure 3C).
Since rCCL2 can activate both CCR2 and CCR5 [25]
we used AZ889 to test if a selective CCR2 antagonist
can prevent CCL2-induced calcium signalling in native
tissue. In DRG neurons, incubation with AZ889 (5 min)
produced a concentration-dependent inhibition of the
rCCL2 (100 nM) evoked calcium response with an IC50
of 1.5 nM (Figure 3D-E). This confirms that neuropathic
DRG neurons show functional CCR2 signalling
mediated by an intracellular calcium rise.
Figure 2 CCL2 modulates action potential firing frequency in
DRG neurons. (A) Current-evoked action potentials from a
representative DRG neuron from CCI rat before during and after
application of CCL2. rCCL2 evoked a concentration-dependent
increase in firing during a depolarizing current step in DRG neurons.
**p < 0.01, ***p < 0.001 vs vehicle. (B) Summary data showing the
efficacy of AZ889 to block rCCL2-mediated excitation of neuropathic
DRG neurons. *p < 0.05 vs vehicle.
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CCR2 activation in DRG neurons
To understand the intracellular mechanism involved in
CCL2-mediated calcium mobilization we next tested if
CCR2 activation produced a release of calcium from
internal stores. In the absence of extracellular calcium,
the peak CCL2-evoked calcium rise was reduced, but
this difference was not significant (p > 0.05, n = 9 cells,
Figure 3F) suggesting that intracellular stores are the
principal source of calcium mediating this response.
It has been previously reported that CCR2 receptors
signal through phospholipase C/inositol trisphosphate
(PLC/IP3)-dependent pathways to intracellular calcium
stores in DRG neurons from focal demyelination mouse
model [24]. To evaluate the contribution of this pathway
in DRG pathophysiology, we used the PLC blocker
U73122. When DRG neurons where incubated in 1 μM
U73122 before (5 min), during and after CCL2 applica-
tion, the evoked calcium mobilization was significantly
blocked (p < 0.05, n = 6 cells, Figure 3G) suggesting
that activation of the PLC/IP3 pathways is necessary for
the CCR2 function in DRG neurons from CCI rats.
Figure 3 CCL2 evokes a calcium-mediated activation of DRG neuronal and non-neuronal cells. A) Representative neuronal (n) and non-
neuronal (g) in bright field (1) and at various times of the fluorescent calcium imaging recording (2-5) indicated in B. Concentration-dependent
calcium rise evoked by CCL2 (black bar, 10, 50, 100 and 300 nM) in DRG neurons (left) and in non-neuronal cells (right). Traces are average
calcium responses for all recorded cells. C) Calcium rise peak normalized to maximal neuronal response represented in a concentration-response
curve (EC50 58.5 nM and 55.6 nM for neuronal and non-neuronal cells respectively). D) and E) Average calcium response curves evoked by 100
nM CCL2 (black bar) in DRG neurons in the presence of AZ889 0.1 nM (n = 9 cells), 1 nM (n = 7 cells), 10 nM (8 cells) and 100 nM (8 cells)
normalized to control responses without AZ889 (IC50 1.5 nM). F) Calcium rise evoked by 100 nM CCL2 (black bar) in DRG neurons from CCI rats
bathed in control conditions (grey) and in the absence of extracellular calcium (black). Peak amplitudes in control and in the absence of
extracellular calcium are not significantly different (p > 0.05). G) Calcium rise evoked by 100 nM CCL2 (black bar) in DRG neurons from CCI
rats bathed in control conditions (grey) and in the presence of U73122 (1 μM). U73122 produced a significant block of the calcium rise peak
(p < 0.05).
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hyperalgesia in neuropathic CCI animals
The contribution of CCR2 signalling to neuropathic
conditions was tested by the ability of AZ889 to reverse
hyperalgesia in vivo. For this procedure, CCI rats were
tested 4 h post administration, corresponding to the
time of peak plasma exposure as determined by the
pharmacokinetic profile (Table 1). When compared with
naive animals, rats with a chronic constriction injury to
the sciatic nerve showed a significant decrease in the
paw withdrawal latencies to radiant heat (10.6 ± 0.4 sec
in naive vs 5.9 ± 0.4 sec in CCI, p < 0.001, data not
shown) and mechanical stimulation (146.4 ± 6.0 g in
naive vs 92.5 ± 4.0 g in CCI, p < 0.001, data not shown).
Systemic administration (p.o.) of AZ889 dose-depen-
dently reversed mechanical and thermal hyperalgesia
responses compared to vehicle-treated neuropathic ani-
mals (p < 0.001, Figure 4A, see Table 2 for EC50).
Importantly, during behavioural studies, no overt signs
of sedation as reported by the locomotor activity assay,
convulsion or aggression were noted up to the maximal
dose of AZ889.
To compare the efficacy of AZ889 with a clinically
validated analgesic, a dose-response study with pregaba-
lin was also conducted. Pregabalin (p.o.) reduced heat
hyperalgesia with a potency 10-fold lower than AZ889
(Figure 4A). Importantly, a clear decrease in muscle
tone was observed in animals treated with the highest
dose of pregabalin (100 mg/kg p.o.) whereas no such
effect was observed with AZ889 (data not shown).
Site of action of CCR2-mediated analgesia
Pharmacokinetic data revealed that the brain to plasma
ratio of AZ889 was 0.23 indicating this compound pene-
trates the central nervous system. Free brain concentra-
tion of AZ889 in satellite animals showed that
pharmacologically relevant concentrations relative to in
vitro potency and selectivity of the compound at CCR2
(within 3- to 5-fold in vitro IC50) were sufficient to
observe thermal and mechanical anti-hyperalgesia effects
in neuropathic animals (Table 2). Based on the close
relationship between free brain concentration and the
in vitro IC50 of AZ889, we wanted to confirm that the
site of action of the analgesic effect of AZ889 was cen-
trally mediated. Thus, spinal intrathecal administrations
of low doses of AZ889 were tested for their anti-hyper-
algesic abilities in rat behavioural assays. As a control,
Table 1 Pharmacokinetic profile of AZ889 with P.O.
administration
Dose
(μmol/kg)
Cmax
(μM)
Tmax
(h)
Bioavailability
(%)
35.03 0.172 4 13.9
Figure 4 Mechanical and heat hyperalgesia in CCI rats.( A )O r a l
administration of AZ889 reverses mechanical and heat hyperalgesia
in the CCI rats (tested 4 h after dosing). Oral administration of
pregabalin reverses heat hyperalgesia in CCI rats (tested 1 h after
dosing). (B) Intrathecal injection of AZ889 (1-30 nM/15 μL) reverses
withdrawal latencies to heat stimulation of the affected paw in CCI
rats (tested 15 min after dosing). Normalized values in parenthesis
on top of the bar show mean % effect for each treatment. (C) Time
course of the reversal of heat hyperalgesia after intrathecal injection
of AZ889 (30 nmol/animal) in CCI rats (tested 15, 30, 60, 120 and
240 min after dosing). All panels, *p < 0.05, **p < 0.01, ***p < 0.001
vs vehicle (i.t. study: one-way ANOVA on the raw data and Holm-
Sidak post hoc test). Normalized values in parenthesis on top of the
bar show mean % effect for each time point.
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rat, produced a dose-dependent reversal of heat hyperal-
gesia (ED50 of 2.3 nmol; maximal reversal of hyperalge-
sia of 78%; Figure 4B) supporting an important central
site of action. Subcutaneous administrations of the same
dose of AZ889 (30 nmol/rat) showed no effect, hence
ruling out the possibility that i.t. administered com-
pound acted outside the CNS.
To determine the time course of the effect of AZ889,
animals were tested 15, 30, 60, 120 and 240 minutes fol-
lowing intrathecal administration of 30 nmol/animal of
AZ889. Time-dependent reversal of thermal hyperalgesia
responses by AZ889 was compared to vehicle-treated
neuropathic animals (*** p < 0.001 and * p < 0.05, Fig-
ure 4C) and naive animals. The peak reversal of hyperal-
gesia was observed 15-30 min post-injection.
Mechanical- and electrical-evoked nociceptive input to
the spinal cord in CCI rats involves CCR2 signalling
To further investigate the mode of action of spinal
CCR2 antagonism, in vivo single cell neuronal record-
ings were tested on evoked neuronal activity in CCI ani-
mals. Administration of AZ889 directly to the exposed
spinal cord produced a significant dose-dependent inhi-
bition of single-unit wide dynamic range (WDR) neuron
activity evoked by innocuous brush (300 nM p <0 . 0 5
compared to vehicle) and noxious pinch (300 nM p <
0.01 compared to vehicle) suggesting an involvement of
spinal CCR2 in modulating somatosensory transmission
in neuropathic conditions. Maximal inhibition of WDR
brush-evoked firing was sustained between 50 and 60
minutes (57.5 ± 8.9% and 57.8 ± 7.9% of baseline activ-
ity respectively) post spinal drug administration (Figure
5A). Sixty minutes after spinal drug administration, nox-
ious pinch-evoked WDR firing decreased to 57.8 ±
11.3% of baseline activity (Figure 5B).
In addition, we evaluated if AZ889 interfered with
spinal sensitization. We used repetitive electrical stimuli
at noxious intensity to induce a spinally-mediated
N-methyl-D-aspartic acid (NMDA)-dependent progres-
sive hypersensitivity of nociceptive flexor reflex,
e.g. wind up [26-28]. In control conditions, repeated low
frequency electrical stimulation of the sural nerve
Table 2 Analgesic profile of AZ889 in CCI neuropathic
rats
Plasma-EC50 (free
#) Brain-EC50 (free
#) Effect at 48
μmol/kg
nM nM % (± SEM)
Mechanical 33 3.8 58 ± 16*
Thermal 80 6.1 60 ± 12*
# Plasma protein binding = 82.6%, brain protein binding = 93.9%.
* Significantly different (p < 0.001) from vehicle treated animals (n = 6-14).
Figure 5 Evoked neuronal spinal activity in CCI rats involves
CCR2 signalling. (A) Innocuous brush-evoked activity of WDR
neurons in CCI rats before, during and after spinal administration of
100 nM and 300 nM AZ889. *p < 0.05, ***p < 0.001 vs vehicle (two-
way ANOVA and Bonferonni post hoc test). (B) Noxious pinch-
evoked WDR neuronal activity before, during and after spinal
administration of 100 nM and 300 nM AZ889 in CCI rats. **p < 0.01,
***p < 0.001 vs vehicle (two-way ANOVA and Bonferonni post hoc
test). (C) Flexor alpha-motoneuron response to repetitive low
frequency C-afferent fibre volleys to the sural nerve in vehicle- and
AZ889-treated CCI rats. AZ889 i.v. infusion of 1 μmol/kg in 15 min
preceded by a loading dose of 2.5 μmol/kg (2.4 μM plasma
concentration) blocked wind-up response. ***p < 0.0001 vs vehicle.
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sitization of the evoked responses (Figure 5C). AZ889
significantly blocked this phenomenon (p < 0.0001, n =
6) suggesting this compound produced analgesia by
interfering with NMDA-dependent spinal wind-up.
Intravenous infusion of AZ889 (2.5 μmol/kg bolus + 1
μmol/kg/0.25 h) achieved a plasma concentration of 2.4
μM confirmed by measuring plasma concentration in a
test animal.
CCL2 activates neuronal and non-neuronal cells in spinal
cord slices from CCI rats
A prerequisite for the involvement of the spinal cord in
analgesia produced by AZ889 is that spinal cells are
activated by CCL2. To evaluate this we used spinal cord
slices from CCI rats and evaluated if neuronal and non-
neuronal cell types were sensitive to CCL2. For these
recordings, calcium imaging acquisition was focused on
lamina I of the dorsal horn. Non-neuronal cells typically
displayed a higher baseline fluorescence level and were
distinguishable by their size and stellar morphology dif-
ferent from the large round shape of the neuronal cell
bodies. In some experiments, neurons were recorded in
patch clamp to confirm the presence of action potentials
upon depolarization (data not shown). In this region,
non-neuronal cells included astrocytes, microglia and
other types of glial cells. Interestingly, bath application
of 50 nM CCL2 induced a calcium rise in both neuronal
and non-neuronal cells. In neurons, CCL2 produced a
mean calcium rise peak of 142.5 ± 87.8% (n = 5, Figure
6A) whereas in non-neuronal cells the calcium response
reached 57.8 ± 42.3% (n = 4, Figure 6B). Pre-incubation
of the spinal cord slices in AZ889 (100 nM) before (5
minutes), during and after the application of rCCL2 (50
nM) significantly blocked the calcium response in both
neuronal and non-neuronal cells (n = 4, Figure 6A-B).
Discussion
Here we provided integrated cellular and pharmacologi-
cal evidence revealing the involvement of CCR2 in the
enhancement of neuronal and non-neuronal excitability
of sensory and CNS cells after nerve injury. Further-
more, our data indicated that these changes in cellular
excitability could be an underlying mechanism of neuro-
pathic pain since both cellular activity and pain scores
were attenuated by a selective CCR2 antagonist, AZ889.
Finally, we identified that analgesia produced by CCR2
antagonism had a major site of action in the spinal cord
where it interfered with pathophysiological sensitization
revealed by evoked wind up. Overall we provided further
evidence to support CCR2 antagonists as an attractive
therapeutic approach for neuropathic pain.
Various lines of evidence have identified CCR2 as an
important mediator of neuropathic pain. CCR2 expres-
sion was increased in various human inflammatory con-
ditions [29] and in rodent neuropathic models
[2,11,19,20,30]. Functionally, CCL2 caused cellular
excitation modifying information processing
[2,4,14,18-20,24]. Mice with CCR2 gene deletion did not
develop mechanical allodynia following nerve injury [2]
which strengthened the hypothesis that CCR2 signalling
could be required for the development of pain hypersen-
sitivity. In addition, CCL2 injections were shown to
decrease pain thresholds indicating that CCR2-CCL2
signalling was also sufficient to develop a hyperalgesic
state [18,31]. Other studies have identified pharmacolo-
gical interventions that prevent hyperalgesia develop-
ment if CCL2 is neutralized prior to the neuropathic
induction [12] giving insight into an eventual CCR2-
mediated treatment for neuropathic pain. CCR2 antago-
nists have been shown to attenuate neuropathic pain
[4,15] but, although well characterized, their selectivity
against other targets and pharmacokinetic properties
remain unknown.
In our study, a novel selective pharmacological tool,
AZ889, was used to characterize the CCL2/CCR2 effects
on pain processing cells and to show that these effects,
particularly in the spinal cord, could account for
AZ889-mediated antinociception. The differentiation
with previously characterized CCR2 antagonists is based
on the particular properties of the compound but also
on the integration of in vitro and in vivo characteriza-
tion to understand the site of action by comparing dif-
ferent routes of administration and using exposure
measurements in relevant tissue to confirm effects. The
selectivity of AZ889 was used to confirm that the rever-
sal of heat and mechanical hyperalgesia is caused by a
selective block of the CCR2 receptor. For this reason,
Figure 6 Neuronal and non-neuronal cells in spinal cord slices
from CCI rats are responsive to CCL2 applications. Both
neuronal (A, grey trace) and non-neuronal cells (B, grey trace) are
responsive to 50 nM CCL2 application (black bar) in spinal cord
slices from CCI rats. Average traces from 8 neuronal and 6 non-
neuronal cells in 4 slices. Error bars show standard error. Pre-
incubation of the spinal cord slices in AZ889 (100 nM) before
(5 minutes), during and after the application of rCCL2 prevented the
calcium response in both neuronal and non-neuronal cells (A and B,
black traces).
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against a panel of over 70 targets and revealed IC50
values greater than 10 μM at each of them. The calcium
mobilization assay demonstrated that AZ889 is 60 times
more selective for CCR2 over CCR5 in blocking the cal-
cium response mediated by these receptors. In vitro effects
of CCL2, which preferentially binds to CCR2 receptor
[21,32], were blocked by AZ889 suggesting a specific
CCR2 excitatory mechanism. Exposure values of AZ889
required to obtain antinociception are less than 5 fold of
the in vitro CCR2 IC50 and within the 60 fold selectivity
window against other targets suggesting that pharmacolo-
gically relevant doses are sufficient to produce a beha-
vioural effect. Thus, AZ889 represents a novel, potent,
selective and functionally active antagonist for the CCR2
chemokine receptor producing analgesia in vivo in the
CCI model at concentrations that are relevant in vitro.
Our results demonstrated novel mechanisms activated
by CCR2 that induced intracellular PLC-dependent cal-
cium mobilization and a modulation of membrane excit-
ability that was translated into increased action potential
output from DRG neurons. CCL2-evoked activation was
also observed as a calcium-mediated excitation occur-
ring in engineered cells expressing CCR2 as well as in
both neuronal and non-neuronal cells from the DRG
and in the spinal cord. Additionally, we provided phar-
macological verification that CCL2-evoked effects were
mediated by CCR2 by using the selective antagonist
AZ889 which confirmed the importance of this receptor
for cellular activation in neuropathic conditions.
Reports analyzing CCR2 expression in neuropathic
conditions showed either predominantly non-neuronal
CCR2 [14,30] or presence of the receptor in both neuro-
nal and non-neuronal cells [18-20]. It is however possi-
ble that different neuropathic models used could explain
variations in CCR2 expression. In the present study,
functional assays were used to show that CCL2 activated
both neuronal and non-neuronal cells in the spinal cord
and DRG. Despite this observation, our results could
indicate either the presence of CCR2 on both cell types
or that CCL2-evoked neuronal activation is indirectly
mediated following glial CCR2 excitation and release of
a gliotransmitter onto neurons. In the later case,
perhaps glial CCR2 could be involved in both CCR2-
mediated hyperalgesia and in the analgesic effect
produced by AZ889.
CCL2-evoked activation of DRG cells had been pre-
viously reported [24]. To our knowledge, our results
were the first demonstrating CCL2-evoked excitation
of both neuronal and non-neuronal cells in the spinal
cord. This excitatory effect appeared to be mediated by
CCR2 since it was prevented by the CCR2 antagonist
AZ889. Our results indicating the sensitivity of spinal
cord cells to CCR2 signalling confirmed the cellular
basis of the spinal site of action of AZ889-produced
analgesia.
Differences in sites of action have a major implication
on drug optimization for therapy. The site of action of
CCR2 antagonists producing analgesia remains a matter
of debate. A peripheral site of action was proposed
based on the predominantly peripheral expression and
activation of CCR2 in a demyelination injury model of
neuropathic pain [17]. CCR2 expression in sensory cells
could support either a peripheral or a central site of
action of CCR2 in analgesia depending on the particular
location of the receptor (nerve, cell body or axon term-
inals in the spinal cord). A central site of action was
suggested based on the spinal CCL2 upregulation and
microglia activation in the spinal cord of CCI animals
[12,30]. Two other findings confirmed a spinal site of
action of analgesia produced by CCR2 antagonists: first,
mechanical allodynia was attenuated following intrathe-
cal injection of CCL2 neutralizing antibody [12] and sec-
ond, release of CCL2 was increased in the spinal cord of
CCI animals following supramaximal electrical stimula-
tion of dorsal roots [12].
Overall, our results were compatible with a primarily
central site of action of analgesia produced by AZ889.
First, pharmacokinetic studies in vivo demonstrated that
AZ889 crossed the blood-brain barrier after systemic
administration. Second, intrathecal or systemic dosing of
AZ889 in CCI neuropathic rats produced similar anti-
nociceptive efficacy in the thermal hyperalgesia beha-
vioural assay suggesting that analgesia was generated in
the spinal cord at concentrations of AZ889 confirmed
with exposure measures fundamental to ensure efficacy
and selectivity. Third, the predominant spinal site of
action of CCR2-based analgesia was also confirmed
when local application of AZ889 to the spinal cord
inhibited WDR neuron excitability. Finally, we identified
that AZ889 prevented spinal wind-up of C-afferent fibre
response suggesting, for the first time, that interference
with synaptic plasticity in the spinal cord could be the
mechanism underlying the analgesic properties of this
compound and CCR2 antagonists in general. The discre-
pancy in site of action between studies could be attribu-
ted to the differences in animal models of neuropathic
pain used and dependent on the particular pathophysiol-
ogy of nerve injury.
The analgesic profile of AZ889 was also compared
with the gold standard benchmark drug pregabalin
[33,34]. As previously reported we showed antinocicep-
tion produced by pregabalin [35,36] with limited efficacy
to reverse thermal hyperalgesia in the CCI model and a
noticeable decrease in muscle tone at the highest dose.
AZ889 demonstrated limited efficacy for heat hyperalge-
sia as well, but the effect was obtained with a dose
10-fold lower than pregabalin without noticeable side
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comparable efficacy to available drugs in the clinic while
providing increased safety. The ability of AZ889 to
reverse completely mechanical but not heat hyperalgesia
could also indicate that a treatment for neuropathic
pain based on a CCR2 antagonist may be specific for
particular indications or modalities. Finally, although
blocking CCR2 signalling had been shown to prevent
the development of neuropathic pain, here we showed
that the more clinically relevant CCR2 antagonism
could reverse an established hyperalgesia state in a neu-
ropathic model. Overall, these studies indicated that
CCR2 antagonism had the ability to inhibit and reverse
both pain behaviour and its neuronal correlates.
Conclusions
We have revealed important contributions of CCR2
receptors on spinal neurons and on evoked excitability
in the spinal cord related to neuropathic pain. We
believe behavioural analgesia shown at relevant pharma-
cological exposures of AZ889 is mediated by major
actions via the spinal cord and that these data support
therapeutic interventions in neuropathic pain by attenu-
ating central CCR2 systems.
Methods
Animals
This study was conducted under a protocol that has
been approved by an ethical committee. The animals
were kept and experiments were performed at our main
site (AZRDM: AstraZeneca R&D Montréal) or at a site
which has accreditation from: CCAC (Canadian Council
on Animal Care), AAALAC (Association for the Assess-
ment and Accreditation of Laboratory Animal Care)
and/or approved by AZ GVC (AstraZeneca Global
Veterinary Council) for study conduct. Male Sprague-
Dawley rats (Harlan) were group-housed in ventilated
cages in a controlled environment room (12-hour light/
dark cycle, 20.5-23.5 °C, relative humidity: 40-70%) with
food (14% Protein Rodent Maintenance Diet, Harlan
Teklad) and water ad libidum.
Drugs
AZ889, a piperazinecarboxamide derivative, was
synthesized at AstraZeneca R&D Alderley Park (UK),
prepared according to the experimental procedure
described in the patent application WO-2006/067401
[37] and selected over other compounds based on its
properties in terms of in vitro potency, bioavailability,
half-life and CNS penetration. All culture reagents
were purchased from Wisent or Sigma unless specified.
rCCL2 and mCCL2/JE/MCP-1 were purchased from
R&D System. Pregabalin was purchased from 3B Scien-
tific Corporation.
Calcium mobilization in heterologous system
Briefly, HEK293 s cells stably expressing rat CCR2 and
the chimeric Gaqi5 were plated (15000 cells per well) in
384-well assay plates in Dulbecco’s modified Eagle’s med-
ium (DMEM) for 24 h in a humidified atmosphere at
37°C in 5% CO2. After removing the medium by inver-
sion, cells were loaded with the calcium-sensitive dye
Fluo4-AM (Molecular Devices), 15 μLp e rw e l lo f4μM
FLUO-4/Pluronic acid mix (1 mM) in buffer and incu-
bated at 37°C for 1 h in a humidified chamber (5% CO2/
95% air). Cells were washed 4 times in Hanks’ balanced
salt solution buffer supplemented with 20 mM HEPES +
0.25% bovine serum albumin at pH 7.4. Different concen-
trations of the test compound (from 10 mM stock in
dimethyl sulfoxide) were added in buffer for 30 min at
37°C in 5% CO2. In this assay, mouse CCL2 was added at
1 nM in buffer (EC50 value in Figure 1) and mobilization
of intracellular calcium was measured online (FLIPR,
Molecular Devices). The EC50 and IC50 values were
determined using 8-point concentration-response curve
using non-linear regression and a four-parameter logistic
model (Prism 4.03 software, GraphPad Software Inc).
Model of peripheral nerve injury
Chronic nerve constriction injury (CCI) was induced as
d e s c r i b e dp r e v i o u s l y[ 3 8 ]i nm a l eS p r a g u e - D a w l e yr a t s
weighing 125-150 g at the time of surgery. Briefly, under
isoflurane anaesthesia, a small incision was made 0.5 cm
below the pelvis, and the biceps femoris and the gluteus
superficialis (left side) were separated. The sciatic nerve
was exposed, isolated, and four loose ligatures (4-0 chro-
mic gut) with 1 mm spacing were placed around it. The
nerve was placed back in its natural position and
the incision sealed with tissue adhesive (VetbondTM).
The animals were allowed to recover for 7-10 days
before conducting any behavioural testing. Animals that
were not gaining weight or were showing clinical signs
of distress (e.g. paralysis, self-mutilation, extensive alo-
pecia) were not included in this study.
Preparation of DRG cultures
Ganglia from L4 to L6 dorsal roots were harvested from
CCI animals, 4 to 19 days post-surgery. The tissue was
enzymatically digested at 37°C for 90 min with collage-
nase-A (2 mg/mL) and papain (1 mg/mL) in DMEM.
Cells were plated on Poly-D-Lysine coated coverslips
and maintained in F12 supplemented with 10% heat
inactivated horse serum, 2 mM glutamine-penicillin-
streptomycin, and 2 ng/ml NGF and GDNF for 1-3 days
in a humidified chamber (5% CO2/95% O2).
Preparation of spinal cord slices
Spinal cord slices from L4 to L6 region were prepared
from CCI animals, 4 to 19 days post-surgery, following
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vent excess bleeding, 20 uL of Xylocaine was injected
intramuscularly at several sites on both sides of the
spinal cord. Under deep anaesthesia a laminectomy
(T11 to L5) was performed. Once exposed, the spinal
cord was isolated and submerged in oxygenated ice-cold
solution containing (in mM): 250 sucrose, 5 KCl, 2
MgSO4, 1.25 NaH2PO4, 26 NaHCO3 and 10 glucose.
The membranes were carefully removed under the
microscope. The tissue was placed in a purposely-built
agar block with a conical hole to support the spinal
cord in an upright position to cut the transverse slices
(300 μm) which were transferred to room temperature
ACSF for calcium imaging containing (in mM): 117
N a C l ,4K C l ,2 . 5C a C l 2 ,1M g C l 2 ,1N a H 2 P O 4 ,2 5
NaHCO3 and 11 glucose.
Whole cell patch clamp recordings
DRG cells maintained for 1-3 days in culture were
transferred to a recording chamber fixed to the stage of
an inverted microscope (Olympus) and constantly per-
fused (0.5 mL/min) with Dulbecco’s phosphate buffered
saline (PBS), a standard extracellular bathing solution
containing (in mM): 137 NaCl; 8.1 Na2HPO4￿7H2O;
2.68 KCl; 1.47 KH2PO4;0 . 9C a C l 2;0 . 5M g C l 2￿6H2Oa t
pH 7 and 275 to 290 mOsm. Whole-cell current-clamp
recordings were performed using an Axopatch 200B
amplifier (Molecular Devices). Signals were filtered at 1
kHz, digitized at 10 kHz (Digidata, Molecular Devices)
and captured and analyzed off-line (Pclamp9 software,
Molecular Devices). Action potentials were recorded
with borosilicate glass patch pipettes (2-6 MΩ) filled
with solution containing (in mM): 110 K-gluconate, 20
KCl, 10 EGTA, 8 NaCl, 10 HEPES, 1 MgCl2 and 4 Mg-
ATP at pH 7.3. Action potentials were evoked through
injection of depolarizing currents and averaged firing
frequency (3 consecutive current steps) was normalized
to the baseline frequency: % of evoked action potentials
= (evoked frequency of firing (Hz) by the drug/evoked
frequency of firing during the baseline (Hz)) × 100.
CCL2 was applied within 50-100 μm from the cell body
(DAD system, ALA Scientific). rCCL2 was dissolved at 1
μM in PBS containing 0.01% bovine serum albumin and
diluted to final concentration in PBS. CCR2 antagonist
AZ889, dissolved in dimethyl sulfoxide and diluted in
PBS to its final concentration, was applied through the
bath perfusion system. Capsaicin 1 mM stock solution
was dissolved in dimethyl sulfoxide and diluted to its
final concentration in PBS.
Calcium imaging recordings
Cells and spinal cord slices were loaded with Fluo4-AM
(4 μM, 30 min) in an oxygenated chamber (5% CO2/
95% O2). DRG cells and spinal cord slices were washed
in PBS and ACSF respectively and placed in a chamber
mounted on the stage of a fluorescent microscope
(Olympus). Tissue was submerged and perfused con-
tinuously with PBS (DRG cells) or oxygenated ACSF
(spinal cord slices). For each time-lapse image, the fluor-
escence intensity (F) was averaged over the soma area.
Changes in fluorescence (ΔF) were measured as relative
changes from baseline fluorescence (F0) and expressed
as:
%ΔF/F =[(F-F )/F ] 00 0 ×100
Calcium responses were elicited by local application of
CCL2 and AZ889 was applied in the bath through the
perfusion system.
Behavioural measurements of nociception
Animals were brought to the laboratory 24 h prior to
behavioural testing for acclimatization. To measure ther-
mal hyperalgesia [40] animals were placed individually,
and allowed to acclimatize for 30 min, on the glass sur-
face (maintained at 30°C) of the thermal stimulator
apparatus (IITC Life Science). A radiant heat beam was
focused onto the plantar paw surface of the injected
limb. The thermal nociceptive response was defined as
the latency between onset of stimulation and paw with-
drawal. The stimulus intensi t yw a ss e ts u c ht h a tw i t h -
drawal latency of naïve rats was approximately 11 s and
stimulus duration was limited to 20 s to prevent tissue
damage in the absence of a withdrawal response. Base-
line thermal testing was performed to identify and
removed from the study animals that did not develop
hyperalgesia (approximately 20% of animals), e.g. with-
drawal latency greater than 8 s and insufficient to distin-
guish from naïve. Paw withdrawal latencies were
calculated as the mean of two trials conducted with 5
min intervals between measures.
Mechanical hyperalgesia was assessed using the
analgesia meter (Ugo Basile). Animals were gently
restrained, and a steadily increasing pressure was applied
to the dorsal surface of a hind paw via a probe with a
dome-shaped tip (diameter of 1 mm). The pressure
required to elicit paw withdrawal was determined with
cut off set at 295 g to prevent tissue damage.
CCI rats and their corresponding naïve controls were
used throughout this study. Our historical data showed
sham-operated animals do not behave differently than
naïve animals and thus were not used for this particular
study. Testing occurred at postoperative day 14. In
order to assess behavioural pathology, baseline hyperal-
gesia was determined 1-2 days before pharmacological
testing. Animals were then randomized and allocated to
treatment groups. Group sizes were based on the need
for achieving a minimum statistical power of 80%. In all
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received. Data were collected from experiments per-
formed by different scientists to avoid any experimental
bias. For systemic dosing, AZ889 was dissolved in 0.5%
methylcellulose plus 0.1% Tween 80 in distilled water
and delivered p.o. For intrathecal administration, injec-
tions were performed under isoflurane anaesthesia and
the rats were placed on a rounded surface to create an
outward curvature of the spine (humped back). By pal-
pation of the spine, the L5-L6 vertebrae were located
and a 25G needle, connected to a microsyringe, was
inserted perpendicular to the vertebral column between
L5-L6 vertebrae. AZ889 (1-30 nmol) or its vehicle (sal-
ine) were injected in a volume of 15 μL/rat and tested
15 min later when the animals had completely recovered
from the light anaesthesia. The percentage of anti-
hyperalgesia for each rat was calculated according to the
following equation: % anti-hyperalgesia = [(value-vehi-
cle)/(naïve-vehicle)]*100. The highest dose of AZ889
was also tested subcutaneously (30 nmol/15 μL/rat) to
rule out peripheral contribution. Sedation and other
locomotor activity side effects were monitored with a
TruScan photo beam tracking device (CBI). AZ889 did
not induce changes in total movement, rest time, ambu-
latory distance, vertical entries and stereotypic move-
ments of the rats.
In vivo electrophysiological recordings
Under isoflurane anaesthesia, the jugular vein, carotid
artery and trachea were cannulated. The animals were
placed in a stereotaxic frame (Narashige), paralyzed with
2 mg/kg i.v. bolus pancuronium bromide and artificially
ventilated (Inspira, Havard Apparatus). Heart rate, ECG,
end tidal CO2 and blood pressure were monitored
throughout the experimental period and maintained
within physiological limits. Core body temperature was
maintained at 36.5-37.5°C throughout the experiment by
means of a heating blanket connected to a rectal tem-
perature probe. Extracellular single unit signals were digi-
tized for off-line analysis (Spike2 software, Cambridge
Electronic Design). Stimulus-evoked responses were ana-
lyzed as the total number of spikes recorded per stimulus
duration period, and corrected by subtracting the extra-
polated spontaneous activity in the same period. Data
was normalized for each animal to the baseline evoked-
response, calculated as the average of the three values
recorded prior to pharmacological administration.
Spinal cord single unit: Extracellular single-unit
recordings of deep (500-1000 μm) convergent dorsal
horn neurons were made with parylene-coated tungsten
m i c r o e l e c t r o d e s( M i c r oP r o b e sI n c ) .E l e c t r o d e sw e r e
advanced vertically with a microdrive manipulator
through segments L4-L5 of the spinal cord via a lami-
nectomy. The spinal cord was held rigid by clamps
rostral and caudal to the exposed section of spinal cord
(L4-5) and a small well was formed with the surround-
ing muscle. Receptive fields of neurons covering one or
two ipsilateral toes were identified using brush and
pinch stimuli. Responses of neurons to transcutaneous
electrical stimuli applied to the centre of the receptive
field were recorded. All neurons selected were wide
dynamic range neurons (WDR), exhibiting a short-
latency Abeta-fibre evoked response (0-20 ms post-sti-
mulus) and Adelta-fibre evoked response (20-90 ms
post-stimulus). These neurons also exhibited longer
latency C-fibre evoked responses (90-300 ms post-sti-
mulus) and post-discharge responses (300-800 ms post-
stimulus). Responses of neurons to brush (artists paint
brush) and pinch (calibrated noxious mechanical pinch)
stimulation of their peripheral receptive fields were
recorded. Three brush strokes and one 5 s pinch stimuli
were applied to the receptive field every 10 min and the
evoked WDR neuronal activity was characterized. Fol-
lowing identification of a WDR neuron and recording of
control, pre-drug brush and pinch-evoked responses (<
15% variance between subsequent control evoked neuro-
nal activity), a 50 μL volume of CCR2 test compound
(100 nM or 300 nM) or vehicle (0.1% BSA in saline)
was administered directly to the exposed spinal cord
[41]. The brush and pinch-evoked responses of spinal
neurons were followed for 70 min at 10-min intervals
following drug administration.
Nociceptive Flexor Reflex: The activity of alpha-moto-
neurons was recorded with silver wire electrodes from
the nerve to the posterior biceps femoris/semitendinosus
muscles in spinalized (T3-T4), anaesthetic free, decere-
brated (cranial contents rostral to the mesencephalon)
CCI animals [42]. The sural nerve was dissected free
and placed on a pair of silver wire stimulating electro-
des. The experiment was started one hour after prepara-
tion, to allow for recovery from the anaesthetic and
spinalization procedures. To quantify the excitability of
the flexor reflex activity spikes were counted during the
following epochs: (1) 10 s spontaneous activity period;
(2) 2 s pinch applied with calibrated forceps (5 × 24
mm rectangular blade surface, sprung at 210 g) on the
three middle toes of the ipsilateral hind paw; (3) 12 s
supra-threshold electrical stimulation to sural nerve
(500 ms square pulse at 1 Hz); each measurement being
separated by at least 50 s. Prior to pharmacological
administration, baseline values were obtained by repeat-
ing the stimulation paradigm for at least 30 min until a
stable reflex level was established. Test compound was
formulated in 20% cyclodextrin in 0.9% saline (pH 7.2)
and infused i.v. to reach a stable plasma concentration.
A blood sample was sampled from one test animal to
confirm the plasma concentration. The nociceptive
responses were measured in a fixed order at 5 min
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and recovery.
Determination of AZ889 levels in plasma and brain tissue
A separate group of naïve rats, satellite animals, not sub-
jected to nociceptive testing were used for plasma and
brain tissue collection in order to establish the PK/PD
relationship of AZ889. At the appropriate time point,
satellite animals were injected with drug using the same
dosing solution and route of administration as the tested
animals. Blood and brain were collected after decapita-
tion. Blood samples were transferred to heparinised tubes
and centrifuged at 3000 g for 5 min. Plasma supernatant
and brain were then collected and frozen (-80°C).
Preparation and analysis of plasma samples
An aliquot of 30 μL plasma sample was precipitated by
addition of 60 μL of acetonitrile containing 0.1% formic
acid and 1 μM of Internal Standard (I.S.). The samples
were centrifuged for 30 min at 9000 × g. After centrifu-
gation, a 10 μL aliquot of the supernatant was directly
injected for LC/MS/MS analysis. The measurement of
AZ889 concentration in plasma was carried out on a
generic HPLC coupled to a mass spectrometer with an
electrospray ionization source in the positive mode
using multiple reaction monitoring. Chromatographic
separations were performed using a generic reverse
phase HPLC C18 column (2.1 × 50 mm, 3 μ). The
mobile phase consisted of 0.1% formic acid in purified
water (solvent A) and 100% acetonitrile containing 0.1%
formic acid (solvent B). The following gradient was
used: 5% to 95% solvent B in 2 min. The flow rate was
constant at 0.750 mL/min and the column temperature
was set at 45°C. Data processing was performed using
the LC/MS/MS software. The first apparent binding
constant of AZ889 was determined in 10% plasma by
equilibrium dialysis. A total drug concentration of 20
m Mw a su s e da tat e m p e r a t u r eo f3 7±2 ° C .T h eb u f f e r
used was isotonic with plasma. The compounds were
dialyzed overnight and the resulting samples were ana-
lyzed using generic HPLC-UV methodology coupled
with Mass spectral peak identification. This value was
used to calculate the free fraction of the drug in plasma.
Preparation and analysis of brain samples
After collection, brains were frozen in liquid nitrogen,
pulverized, samples were weighed, and buffer was added
(2× the weight). Samples (30 μL) were then homoge-
nized, precipitated by addition of 60 μL of acetonitrile
containing 0.1% formic acid and 1 μM of Internal Stan-
dard (I.S.) and centrifuged for 30 min at 9000 × g. 10
μL of the supernatant was injected for LC/MS/MS ana-
lysis. The procedure for the measurement of AZ889 in
brain homogenate is the same as described above for
plasma samples.
The degree of brain binding was assessed by equili-
brium dialysis utilizing a semi-permeable membrane
with a molecular cut-off of 12-14 kDa (HTD Dialysis).
The brains of three drug-free control rats were removed
and diluted in PBS to prepared tissue homogenate sam-
ples. AZ889 (1 μM) was added to the homogenate. In
the dialysis unit, 125 μl of samples spiked in homoge-
nate was added to one side of the dialysis chamber and
phosphate buffer to the other side. The plate was then
placed in a shaker/CO2-incubator to equilibrate for 18
hrs at 37°C. Following incubation, 50 μla l i q u o t sf r o m
each of the two cells of the equilibrium chamber were
collected and transferred to a 96 deep well plate. 50 μl
of blank brain homogenate was added to the samples
f r o mt h eb u f f e rs i d ea n d5 0μl of buffer was added to
the homogenate side. An additional 50 μl of water was
added to all samples. 150 μl of cold acidified acetonitrile
was added to each sample in order to precipitate plasma
proteins. Samples were centrifuged and the supernatant
analyzed by LC-MS/MS. Diluted brain tissue homoge-
nate were corrected to determine the unbound fraction
(Fu) in undiluted tissue:
Undiluted Fu = (1/D)/([(1/Fu )-1]+1/D) 2
Fu2 is unbound fraction measured and D is dilution
factor of brain tissue. Control samples were utilized to
calculate recovery and stability and the reference com-
pound propanolol was assayed along with AZ889.
Data analysis
Data for behavioural and electrophysiological studies are
presented as a mean of transformed data ± SEM. Unless
specified, statistical significance was determined using
two-way repeated measures ANOVA followed by a
Holm-Sidack post hoc test on normalized data or non-
parametric ANOVA followed by appropriate multiple
comparison tests (SigmaStat ver. 3.11, Systat Software
Inc.). p-values of less than 0.05 were regarded as signifi-
cant. Plasma and brain EC50 values in behavioural stu-
dies were determined from 5-point concentration-
response curves using non-linear regression and a sig-
moidal variable slope logistic model (Prism 4.03, Graph-
Pad Software Inc.). The EC 50 values were defined as
the 50% reversal concentration from the regression
curve.
Additional material
Additional file 1: Mouse and rat CCL2 induce intracellular calcium
mobilization in HEK293 s cells expressing CCR2 with similar
efficacy. Mouse and rat derivative of CCL2 evoked calcium activation of
HEK293 s cells expressing CCR2 with an EC50 value of 0.5 and 0.8 nM
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data shown is the average of 3 independent experiments.
Additional file 2: In-vitro characterization of AZ889 selectivity
against other biological targets. Selectivity of AZ889 assessed against a
broad panel of targets, including (G protein-coupled receptors) GPCRs,
ligand-gated receptors, ion channels, transporters and enzymes
expressed in a heterologous system. AZ889 was inactive (less than 50%
effect at 10 μM) on all targets.
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